Literature DB >> 12962163

Thiazolidinedione-associated congestive heart failure and pulmonary edema.

Asra Kermani1, Abhimanyu Garg.   

Abstract

OBJECTIVE: To evaluate the effect of thiazolidinediones on the development of cardiac failure and pulmonary edema during treatment of type 2 diabetes mellitus. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 6 men (aged 66 to 78 years) treated at our institution between August 1, 2001, and May 21, 2002, who had type 2 diabetes and developed signs and symptoms of congestive heart failure and pulmonary edema after 1 to 16 months of therapy with pioglitazone or rosiglitazone.
RESULTS: Four patients had chronic renal insufficiency; only 1 had ischemic cardiomyopathy. Symptoms resolved promptly in all 6 patients after administration of diuretics and discontinuation of the thiazolidinedione.
CONCLUSION: We conclude that thiazolidinediones can cause or exacerbate heart failure and pulmonary edema and should be avoided in patients with left ventricular dysfunction or chronic renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12962163     DOI: 10.4065/78.9.1088

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  20 in total

1.  Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.

Authors:  Li Zhou; Gang Liu; Zhanjun Jia; Kevin T Yang; Ying Sun; Yutaka Kakizoe; Mi Liu; Shufeng Zhou; Ren Chen; Baoxue Yang; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-04

2.  Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.

Authors:  Fadia T Shaya; James Y Shin; Daniel Mullins; Hugh O Fatodu; Anna Gu; Elijah Saunders
Journal:  J Natl Med Assoc       Date:  2005-04       Impact factor: 1.798

3.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Authors:  Michel Komajda; John J V McMurray; Henning Beck-Nielsen; Ramon Gomis; Markolf Hanefeld; Stuart J Pocock; Paula S Curtis; Nigel P Jones; Philip D Home
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

Review 4.  Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Authors:  Toshikazu Yamanouchi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

5.  Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

Authors:  G-H Hao; X-L Niu; D-F Gao; J Wei; N-P Wang
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

6.  Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.

Authors:  Ji-Young Park; Kyoung-Ah Kim; Jae-Gook Shin; Ki Young Lee
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

Review 7.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 8.  Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

Authors:  Janaka Karalliedde; Robin E Buckingham
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Insulin resistance due to lipid-induced signaling defects could be prevented by mahanine.

Authors:  Anindita Biswas; Sushmita Bhattacharya; Suman Dasgupta; Rakesh Kundu; Sib Sankar Roy; Bikas C Pal; Samir Bhattacharya
Journal:  Mol Cell Biochem       Date:  2009-10-14       Impact factor: 3.396

10.  Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Authors:  David N Juurlink; Tara Gomes; Lorraine L Lipscombe; Peter C Austin; Janet E Hux; Muhammad M Mamdani
Journal:  BMJ       Date:  2009-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.